Target intelligence / Profile preview

CDH2 antisense RNA 1 (CDH2-AS1)

Target
CDH2-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Other (non-protein-coding RNA)
01

Overview

CDH2 antisense RNA 1 (CDH2-AS1) is a long non-coding RNA gene transcribed in the antisense direction relative to the CDH2 (N-cadherin) gene. While specific functional studies on CDH2-AS1 are limited, antisense long non-coding RNAs typically regulate the expression of their sense partner gene (in this case, CDH2), potentially affecting RNA stability, translation, or chromatin state by acting in cis (on the paired locus) or trans (on other loci). CDH2 (N-cadherin) has established roles in cell adhesion, signaling, and disease, notably in neurodevelopment and cancer, suggesting that regulatory changes at the CDH2-AS1 locus may influence similar pathways. However, CDH2-AS1 itself is not a protein-coding gene, drug target, or therapeutic receptor, and molecular details regarding its role in health or disease remain under investigation.

02

Mechanism of action

Not established for drugs, as CDH2-AS1 is not a direct pharmacological target. Regulatory RNA may act by modulating stability, translation, or transcription of its sense counterpart (CDH2) or nearby genes in cis or trans, by RNA-RNA, RNA-protein, or chromatin interactions.

03

Biological functions

Regulation of gene expression (especially CDH2/N-cadherin)Potential roles in cancer cell proliferation, migration, and invasion (by analogy to other antisense RNAs; specific details for CDH2-AS1 are not well characterized)Epigenetic regulation
04

Disease associations

Cancer

Beyond the preview

Go deeper on CDH2 antisense RNA 1 (CDH2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDH2 antisense RNA 1 (CDH2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call